Abstract
Recently, most clinical trials are designed on the basis of protein expression or gene amplification of specific genes. Although, only ERBB2 amplification showed targetable biomarker in advanced gastric cancer (AGC). This study aimed to evaluate the profile of gene alterations and protein expression in AGC by using detect by next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
